Suppr超能文献

用于功能定义的正常和恶性乳腺干/祖细胞的检测。

Assays for functionally defined normal and malignant mammary stem cells.

机构信息

Laboratory of Stem Cell and Cancer Biology, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.

Laboratory of Stem Cell and Cancer Biology, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.

出版信息

Adv Cancer Res. 2019;141:129-174. doi: 10.1016/bs.acr.2018.12.004. Epub 2019 Jan 17.

Abstract

The discovery of rare, heterogeneous self-renewing stem cells with shared developmental and molecular features within epithelial components of mammary gland and breast cancers has provided a conceptual framework to understand cellular composition of these tissues and mechanisms that control their number. These normal mammary epithelial stem cells (MaSCs) and breast cancer stem cells (BCSCs) were identified and analyzed using transplant assays (namely mammary repopulating unit (MRU) assay, mammary tumor-initiating cell (TIC) assay), which reveal their latent ability to regenerate respective normal and malignant epithelial tissues with self-renewing units displaying hierarchical cellular differentiation over multiple generations in recipient mice. "Next-generation" methods using "barcoded" normal and malignant mammary cells, with the help of next-generation sequencing (NGS) technology, have revealed hidden complexity and heterogeneous growth potential of MaSCs and BCSCs. Several single markers or combinations of markers have been reported to prospectively enrich MaSCs and BCSCs. Such markers and the extent to which they enrich for MaSCs and BCSCs activity require a critical appraisal. Also, knowledge of the functional assays and their limitations and harmonious reporting of results is a prerequisite to improve our understanding of MaSCs and BCSCs. This chapter describes evolution of the concept of MaSCs and BCSCs, and specific methodologies to investigate them.

摘要

在乳腺和乳腺癌的上皮成分中发现具有共同发育和分子特征的稀有、异质自我更新干细胞,为理解这些组织的细胞组成以及控制其数量的机制提供了一个概念框架。这些正常乳腺上皮干细胞(MaSCs)和乳腺癌干细胞(BCSCs)是通过移植实验(即乳腺重建单位(MRU)测定、乳腺肿瘤起始细胞(TIC)测定)来鉴定和分析的,这些实验揭示了它们潜在的能力,即在受体小鼠中以自我更新的单位再生各自的正常和恶性上皮组织,显示出多代的分层细胞分化。使用下一代测序(NGS)技术的“带条码”正常和恶性乳腺细胞的“下一代”方法揭示了 MaSCs 和 BCSCs 的隐藏复杂性和异质生长潜力。已经报道了几种单一标记物或标记物组合来前瞻性地富集 MaSCs 和 BCSCs。这些标记物以及它们富集 MaSCs 和 BCSCs 活性的程度需要进行批判性评估。此外,了解功能测定及其局限性以及结果的和谐报告是提高我们对 MaSCs 和 BCSCs 理解的前提。本章描述了 MaSCs 和 BCSCs 概念的演变,以及研究它们的特定方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验